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Hyperinsulinism as the culprit: surgery provides the evidence
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In this “clinical” contribution to theBench to Clinic Symposia, we willshow data to support the hypothesis
that fasting hyperinsulinemia is the initial
underlying cause of type 2 diabetes mel-
litus (T2DM) and that the remission of the
disease following bariatric surgery may be
due to the correction of hyperinsulinemia.
The intent of this article is to elicit critical
thinking about the pathophysiology of
T2DM in view of the effects of surgery
and to open debate. If our hypothesis is
correct, then more research resources
should be focused on the cause(s) of fasting




hyperglycemiadThe study of dia-
betes has always focused on glucose.
Whether the diagnosis was made by the
attraction of flies to urine as described in
ancient India in 1552 BC (1), the sweet
taste of the urine noted by Shushruta in
400 BC (2), or our current dependence on
fasting blood glucose levels, HbA1c, and
glucose tolerance curves, the severity of
the disease is still measured by the level
of hyperglycemia.
Similarly, our therapeutic directions
also aim, almost exclusively, to reverse the
hyperglycemia. In 1921 when Banting
and Best reported that a pancreatic ex-
tract reversed the soaring glucose levels
following a pancreatectomy in a dog, the
use of insulin spread rapidly to children
and adults alike. By the time Sir Harold
Percival Himsworth noted, in 1936, that
there were at least two types of diabetes
(3), the objectives of T2DM treatment
were already set; goals that still continue
today. Even though type 1 diabetes
mellitus (T1DM) and T2DM are virtually
two opposite diseases, i.e., a total lack of
insulin production versus abnormally
high levels, the therapeutic goals for
both entities continue to be the same:
lower glucose levels by 1) giving insulin,
2) increasing insulin production, and/or
3) decreasing insulin resistance.
Is the primary lesion
of T2DM insulin resistance
or insulin secretion?dThe pre-
vailing view of T2DM progression (4)
is that the disease is due to an early and
progressive loss of insulin sensitivity.
To maintain homeostatic levels of glucose,
b-cells increase insulin secretion to over-
come insulin resistance in peripheral tis-
sues (glucose disposal) and liver (glucose
production). T2DM occurs when the
b-cells “fail” to produce adequate insulin
to meet these demands.
The rise and later fall in insulin se-
cretion with the progression of T2DM is
depicted nicely by the glucose tolerance
curves that we published in 1992 (Fig. 1)
(5). In the lean subjects, glucose homeo-
stasis is achieved by relatively low con-
centrations of insulin. Glucose-induced
insulin secretion increases with the devel-
opment of obesity and rises even more in
the prediabetic state, i.e., impaired glu-
cose tolerance (IGT). As susceptible indi-
viduals progress from early T2DM (FBS
,140 mg/dL) to advanced disease (FBS
.140 mg/dL), peak insulin secretion
declines.
In the traditional view of T2DM, the
rise in insulin secretion is due to the
primary lesion, i.e., increasing insulin
resistance and the hyperglycemia is due
to the failure of b-cells to produce enough
insulin. The curves in Fig. 1, however, in
addition to documenting the decreasing
levels of insulin secretion with the pro-
gression from IGT to T2DM with FBS
.140 (line A in Fig. 1), also show that
even with progression of the disease, the
maximum insulin concentration is still
twice as high as in euglycemic lean indi-
viduals (line B in Fig. 1) and, more impor-
tant, the basal levels of insulin secretion
continue to rise as the disease worsens
(line C in Fig. 1).
The remarkable extent of the hyper-
insulinemia is also documented in Fig. 2.
T2DM patients with FBS.140 have basal
insulin levels that are nine times higher
than those measured in euglycemic lean
patients.
These data suggest that the difference
between the nondiabetic and the diabetic
patients is the “insulin baseline,” perhaps
due to toomuch insulin production in the
fasting state rather than an inability to se-
crete enough insulin in response to a
meal. Such a view would be supported
by the finding that basal-state hyperinsu-
linemia in healthy normoglycemic adults
is predictive ofT2DMover a 24-year follow-
up (6).
Because the focus of our hypothesis is
on the initial cause of T2DM, our discus-
sion is limited to early- andmid-stage dis-
ease, i.e., patients with FBS#200 mg/dL.
We are fully aware of studies in patients
with severe, late-stage diabetes, i.e., with
FBS levels$250 mg/dL, in which the hy-
perinsulinemia of T2DM is reversed as the
b-cells eventually fail to produce enough
insulin (7). With final progression of the
disease, T2DM becomes similar to clinical
presentation of T1DM in that a more ab-






and remarkable ability of bariatric surgery
to produce full and durable remission of
T2DM (8–13) now offers a new opportu-
nity to review our concepts about the
onset of diabetes since, providentially,
the Roux-en-Y gastric bypass (RYGB)
provides the unusual opportunity to
study patients with T2DM and, after the
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surgery, to assess these same individuals
again without the disease.
Our studies as early as 1992 had
demonstrated that correction of fasting
glucose after bariatric surgery was ac-
companied by the rapid correction of
hyperinsulinemia and, as far as we can de-
termine, most, if not all, of the studies of
diabetes remission after RYGB have also
observed lowering of fasting insulin levels.
To investigate the relative importance
of excessive insulin secretion in early- and
mid-stage T2DM, we studied obese-
nondiabetic and obese-diabetic patients
(FBS of 1646 16 and HbA1c of 8.76 0.5)
before they had gastric bypass surgery
and again 1 week and 3 months after sur-
gery. A group of lean control subjects was
also studied for comparison. Data from
our article by Reed et al. (14) has been
redrawn and is shown in Fig. 3.
Prior to the Roux-en-Y surgery, basal
insulin levels in obese T2DM subjects are
so high that the b-cells can no longer re-
spond to food intake with additional in-
sulin secretion (Fig. 3A). Within a week
after the surgery, however, along with the
correction of glucose levels and resolution
of the T2DM, basal insulin levels return to
normal and the food stimulated spike of
insulin secretion is restored to levels equal
to normal lean control subjects (Fig. 3B
and C).
These data demonstrate that theb-cells
in the diabetic patients, even after a decade
of disease, still retain capacity for insulin
secretion sufficient to produce a completely
normal insulin response immediately after
surgery. Accordingly these results suggest
that hyperinsulinemia is the primary lesion
in T2DM, and the inability to respond to a
mixed meal before surgery is due to the
already elevated basal insulin secretion.
Exploring the
hyperinsulinemia of
T2DMdThere are at least three possi-
ble explanations for the excessive basal
insulin secretion in T2DM that seem
reasonable: insulin secretion is elevated
1) as a feedback mechanism to overcome
insulin resistance, 2) in response to
changes in plasma glucose or plasma
free fatty acids, or 3) in response to a
signal from the gut. Since the only inter-
vention with bariatric surgery is imposed
on the gut, the third explanation seems
most plausible and forms the basis of a
new hypothesis that will be discussed
later.
To investigate if fasting insulin is
reduced after gastric bypass surgery be-
cause of changes in glucose, free fatty
acids, and/or insulin resistance, the values
for fasting insulin from our study men-
tioned above (14) are plotted against val-
ues for glucose, NEFA, and insulin
sensitivity index (Fig. 4A–C)
In agreement with many other re-
ports, prior to surgery, fasting glucose,
nonesterified fatty acids (NEFAs), and in-
sulin were higher in obese than in lean sub-
jects and even higher in patients with
diabetes. Prior to surgery there was a clear
direct relationship between 1) fasting glu-
cose and fasting insulin (Fig. 4A), as well as
2) NEFAs and insulin (Fig. 4B), and 3) an
inverse relationship between insulin sensi-
tivity and insulin (Fig. 4C).
If fasting insulin is reduced after
bariatric surgery because of changes in
glucose, free fatty acids, and/or insulin
sensitivity, then plasma insulin would be
predicted to follow the presurgery regres-
sion line to a lower level of both parame-
ters. The results were in stark contrast to
this prediction because after surgery fast-
ing insulin levels were as low as those of
lean control subjects irrespective of the
fasting glucose, free fatty acids, or insulin
sensitivity (Fig. 4A–C).
These findings demonstrate that after
gastric bypass surgery, fasting insulin is
independent of the effects of fasting glu-
cose, fasting free fatty acids, and insulin
sensitivity. This “uncoupling” or disasso-
ciation of fasting insulin from BMI (kg/
m2), fasting glucose, and insulin sensitiv-
ity was also seen in nondiabetic subjects
who were studied in a weight stable con-
dition more than one year after gastric by-
pass surgery (14,15). From these results
we conclude that correction of hyperinsu-
linemia is not secondary to changes in
glucose, free fatty acids, insulin sensitiv-
ity, or BMI but is a primary metabolic




reversal of diabetes?dIt is not
intuitively obvious that lowering fasting in-
sulin would also reduce glucose levels, i.e.,
improve diabetes. If insulin is suppressing
Figure 1dGlucose tolerance curves in five cohorts: normal lean, normal obese, IGT, early
T2DM, and advanced T2DM (data previously published [5]). While there is a reduction in peak
insulin secretion with progress of T2DM (A), the peak insulin secretion is still higher in advanced
disease than in normal subjects (B) and there is an increase in basal insulin secretion (C).
Figure 2dFasting insulin in normal lean,
normal obese, IGT, early T2DM, and advanced
T2DM (data previously published [5]).
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liver glucose production, then lowering in-
sulin should increase glucose, i.e., make
diabetes worse with a corresponding in-
crease in hepatic glucose output.
Plasma glucose concentration after a
12-h fast is primarily regulated by the rate
of hepatic gluconeogenesis, which in turn
is regulated by insulin, glucagon, and
glucocorticoids. The decrease in insulin
after RYGB would be counter-regulatory
to reducing gluconeogenesis. Likewise,
the changes in the concentrations of
glucagon, cortisol, and corticocosterone
in patients with diabetes after RYGB do
not provide a mechanism to explain the
reduction in gluconeogenesis (W.J.P.,
G.L.D., unpublished data).
Another explanation could be regula-
tion of gluconeogenesis through substrate
supply. Consoli et al. (16) demonstrated
that appearance rates of lactate and alanine
were greater in diabetic patients than in
nondiabetic patients. Likewise, conversion
rates of lactate and alanine to glucose were
greater in diabetic subjects.
To examine if changes in lactate pro-
duction might explain the changes in
fasting glucose, we assayed plasma sam-
ples from the study mentioned above
(14). Before surgery, fasting lactate con-
centrations were significantly correlated
with fasting glucose in the diabetic group
(Fig. 5A). After RYGB surgery, lactate was
dramatically reduced in diabetic patients
(Fig. 5B). We also have preliminary data
(W.J.P., G.L.D., unpublished data) that
fasting concentrations of pyruvate and al-
anine are reduced after RYGB in the same
fashion as lactate. The reduction in lactate
after surgery is related to the decreases in
fasting glucose (Fig. 5C). Although corre-
lations do not prove cause and effect,
these data lead us to speculate that a re-
duction in production of lactate reduces
the substrate for gluconeogenesis and
thus leads to lower plasma glucose con-
centration after RYGB.
The questions that remain are why is
fasting lactate high in a diabetic patient,
and how does RYGB reduce it to normal?
The most likely answer is that the muscle
Figure 3dPlasma insulin in obese nondiabetic
and diabetic patients after a mixed-meal chal-
lenge. Redrawn from the data published by Reed
et al. (14). A lean control group is shown each
time for comparison before surgery (A), a week
after surgery (B), and 3 months after surgery
(C).
Figure 4dCorrelations of fasting insulin with fasting plasma glucose (A), fasting plasma free fatty
acids (NEFAs) (B), and insulin sensitivity index (ISI) (C). Fasting glucose, fasting insulin, and ISI
were previously reported (14). Group symbols: square = lean control group; triangle = obese (non-
diabetic) group; circle = diabetic group. Time symbols: black square, triangle, and circle = presurgery;
white triangle and circle = week of surgery; gray triangle and circle = 3 months postsurgery. L = lean
control group; OB = obese (nondiabetic) group before surgery; DB = diabetic (obese) group before
surgery; OA = obese group after surgery; DA = diabetic group after surgery. wk, week; mos, months.
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cannot manage the large excess of “fuel.”
In spite of insulin resistance, it is likely
that the muscle is taking up more glucose
than it needs or can store during fasting
hyperinsulinemia. Once it is converted to
glucose 6-phosphate, the only way for the
muscle to “export” carbons is through
conversion to pyruvate with subsequent
conversions to lactate and alanine and
transport into blood.
The concurrently elevated levels in
fasting glucose and lactate in diabetic
patients suggest an upregulated Cori cy-
cle. In the Cori cycle, lactate produced by
muscle goes to the liver where it is con-
verted to glucose and then returned to the
muscle where lactate is again formed
through glycolysis. Since hyperglycemia
is an undesirable outcome we might say
that we have a “vicious Cori cycle” in di-
abetic patients. After RYGB, both fasting
insulin and lactate are reduced, which
leads us to speculate that the correction
of hyperinsulinemia leads to less gluco-
neogenic substrate production and reso-
lution of hyperglycemia.
A new hypothesis for the
cause of diabetesdOur results
from these studies of diabetic patients
who have remission of diabetes after RYGB
lead us to propose a new hypothesis for the
mechanism causing diabetes and how
RYGB is able to reverse the disease.
T2DM starts with a diabetogenic signal
from the gastrointestinal (GI) tract to the
islets that causes a chronic and increasing
basal hyperinsulinemia that in turn blunts
the normally spiking insulin response to a
meal. This, plus the muscle insulin resis-
tance that accompanies diabetes, reduces
glucose clearance. Further, during over-
night fasting, this continuous basal hyper-
insulinemia causes the muscle to release
chronically high amounts of gluconeo-
genic substrates with subsequent chroni-
cally elevated hepatic production of
glucose. This situation is diagramed
in Fig. 6.
When a diabetic patient has an RYGB,
the GI diabetogenic signal is no longer gen-
erated, and the fasting hyperinsulinemia
is corrected. Lowering fasting insulin
results in lower production of pyruvate,
lactate, and alanine in muscle. and gluco-
neogenesis in liver is subsequently re-
duced. With lower concentrations of
insulin in the fasting state, insulin secre-
tion in response to a meal is “normalized,”
and the muscle can respond by lower glu-
cose uptake during fasting and increased
glucose uptake in response to a meal.
Conclusions and
implicationsdThe hypothesis that
hyperinsulinemia is the underlying
mechanism causing diabetes is not new.
Jesse Roth and colleagues (6,17) made a
strong case for fasting hyperinsulinemia
causing insulin resistance and devel-
opment of diabetes. In her Banting
Lecture at the 2011 American Dia-
betes Association Scientific Sessions,
Dr. Barbara Corkey (18) (who has
authored the “bench” contribution for
this Bench to Clinic Symposia) presented
convincing evidence in animals for the
Figure 5dPlasma lactate in normal lean control subjects and in diabetic and nondiabetic (obese)
patients before and after RYGB. Fasting plasma samples from the study reported by Reed et al.
(14) were analyzed for lactate. A: Correlation of fasting plasma lactate with fasting plasma
glucose in diabetic patients before surgery. B: Fasting plasma lactate in diabetic and nondiabetic
(obese) patients before and after surgery. The mean value 6 SEM for a control lean group is
shown as a solid6 the dashed lines. White bars show data prior to surgery, black bars show data
at 1 week after surgery, and gray bars show data at 3 months after surgery. C: Correlation
of fasting plasma lactate and fasting plasma glucose in lean, obese, and diabetic groups before and
after RYGB. Group symbols: square = lean control group; triangle = obese (nondiabetic) group;
circle = diabetic group. Time symbols: black square, triangle, and circle = presurgery; white tri-
angle and circle = week of surgery; gray triangle and circle = 3 month postsurgery. L = lean control
group; OB = obese (nondiabetic) group before surgery; DB = diabetic (obese) group before surgery;
OA = obese group after surgery; DA = diabetic group after surgery. wk, week; mos, months.
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development of hyperinsulinemia and in-
sulin resistance. Our contribution to the
discussion comes from the observation in
man that fasting insulin rises with the pro-
gression of T2DM and normalizes to levels
like lean control subjects almost immedi-
ately after gastric bypass surgery. This cor-
rection of hyperinsulinemia after RYGB
occurs simultaneously with the full and
durable resolution of diabetes and is inde-
pendent of changes in weight loss, insulin
sensitivity, glucose, or free fatty acids. The
primary manipulation in the surgery is ex-
clusion of food from a portion of the GI
track. Thus, it seems reasonable to pro-
pose that a diabetogenic signal from the
gut to the islets is the cause of hyperinsu-
linemia. Remission of diabetes and correc-
tion of pathologically high fasting levels of
insulin after RYGB is accompanied by re-
duced levels of lactate. From this we fur-
ther propose that remission of diabetes is
due to reduced lactate production in mus-
cle and subsequent normalization of sub-
strate driven glucose production through
gluconeogenesis.
If this hypothesis, i.e., that the critical
lesion in T2DM is hyperinsulinemia, is
true, the treatment of T2DM with insulin
needs review. While insulin may be re-
quired in the very late stages of T2DM
when there is no longer enough b-cell re-
serve, it might be harmful to administer the
hormone when the intrinsic fasting basal
levels are still elevated. We do not treat hy-
perthyroidism with thyroxine or Cushing
syndrome with cortisone; should we be
treating T2DM, a disease characterized by
hyperinsulinemia, with insulin?
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